feedback

Course Director

Suresh S. Ramalingam, MD, FACP, FASCO
Suresh S. Ramalingam, MD, FACP, FASCO

Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Faculty

Hossein Borghaei
Hossein Borghaei, DO, MS

Fox Chase Cancer Center
Philadelphia, Pennsylvania

Leora Horn
Leora Horn, MD, MSc, FRCPC

Vanderbilt Ingram Cancer Center
Vanderbilt University Medical Center
Nashville, Tennessee

Accredited by

Medical Learning Institute, Inc.

View Activity Materials

Activity Description

Immune checkpoint inhibitors have firmly established their role as a major component of the lung cancer treatment arsenal. In the first-line setting of advanced NSCLC, there are a number of monotherapy and combinatorial strategies (such as combining immune checkpoint inhibitors with chemotherapy regimens, antiangiogenic therapies, and other immunotherapies with non-redundant mechanisms of action) that have FDA-approved indications and are recommended in various best practice guidelines. In addition, increasing evidence is supporting the use of immunotherapies in locally advanced and earlier disease settings, including as neoadjuvant and adjuvant treatments in patients with resectable NSCLC. More recently, the immunotherapy era arrived in SCLC, with new approvals in different settings. Other novel therapies have also improved patient outcomes in extensive-stage SCLC, such as transcription inhibitors.

This educational on-demand activity based on a recent live webcast features a panel of leading experts who engage in candid conversations about the modern management of lung cancer. In addition to reviewing the essential established and new clinical data and approvals/indications of immunotherapies, combinations, and other novel treatment options for NSCLC and SCLC, they discuss insightful registry and survey findings regarding patient perspectives, experiences, and needs, as well as the increasing importance of individualizing treatment selection and patient engagement in care planning. Evidence reviews are framed with case scenarios to illustrate the nuances of clinical decision-making in the context of a complex treatment landscape and a variety of tumor-, patient-, and treatment-related factors that should inform these decisions.

Target Audience

This activity has been designed to meet the educational needs of oncologists and other clinicians involved in the management of lung cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:
  • Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC
  • Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer
  • Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum
  • Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care
  • Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer

Providership, Credit, and Support


This CME/MOC activity is jointly provided by Medical Learning Institute, Inc., GO2 Foundation for Lung Cancer, and PVI, PeerView Institute for Medical Education.

This activity is supported through educational grants from Bristol Myers Squibb, Jazz Pharmaceuticals, Inc., and Merck & Co., Inc.

Physician Continuing Medical Education

ACCMEThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc., GO2 Foundation for Lung Cancer, and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC Credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Faculty Disclosures

Chair
Suresh S. Ramalingam, MD, FACP, FASCO
Professor of Hematology and Medical Oncology
Director, Division of Medical Oncology
Roberto C. Goizueta Chair for Cancer Research
Assistant Dean for Cancer Research
Deputy Director, Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Suresh S. Ramalingam, MD, FACP, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Merck & Co., Inc.; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Advaxis, Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Merck & Co., Inc.; Takeda Pharmaceutical Company Limited; and Tesaro.

Faculty
Hossein Borghaei, DO, MS
Professor and Chief, Thoracic Oncology
The Gloria and Edmund M. Dunn Chair in Thoracic Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Hossein Borghaei, DO, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; Axiom; BioNTech; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Cantargia AB; Celgene Corporation; Daiichi Sankyo Company, Limited; Eli Lilly and Company; EMD Serono, Inc; Genentech, Inc. ; Genmab A/S; GLG Pharma, Inc.; Huya Bioscience International; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer, Inc.; PharmaMar; Regeneron; Rgenix; Sonnet BioTherapeutics, Incand Takeda Pharmaceuticals U.S.A., Inc.
Grant/Research Support from Bristol Myers Squibb/Eli Lilly and Company; Celgene Corporation/Merck & Co., Inc.; and Millennium: The Takeda Oncology Company.
Honoraria from Amgen Inc.; Daiichi Sankyo Company, Limited; and Pfizer, Inc.
Stock Shareholder in Rgenix and Sonnet BioTherapeutics, Inc.
Data Safety Monitoring Board for CAR T Program; Incyte; Takeda Pharmaceuticals U.S.A., Inc.; and University of Pennsylvania.
Other Financial or Material Support for travel for Amgen Inc.; Bristol Myers Squibb; Eli Lilly and Company; EMD Serono, Inc; Genentech, Inc.; and Merck & Co., Inc.

Leora Horn, MD, MSc, FRCPC
Ingram Associate Professor of Cancer Research
Director Thoracic Oncology Program
Vanderbilt Ingram Cancer Center
Assistant Vice Chairman for Faculty Development
Vanderbilt University Medical Center
Nashville, Tennessee

Leora Horn, MD, MSc, FRCPC, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen; AstraZeneca; Bayer Corporation; EMD Serono; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; and Pfizer Inc.
Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; and Xcovery.

Planning Committee Disclosures

The planners from Medical Learning Institute, Inc., the accredited provider, PeerView Institute for Medical Education, and GO2 Foundation for Lung Cancer, joint providers, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Content/Peer Reviewer Disclosures

The following Content/Peer Reviewers have nothing to disclose:

Natalie I. Vokes, MD
Stacy L. Sims, MSN, RN, CMCN

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain MOC credit. There are no prerequisites and there is no fee to participate in this activity or to receive MOC credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

About This CME/MOC Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2020, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.